tacrolimus market size, tacrolimus market growth, tacrolimus market drivers, tacrolimus market share, tacrolimus market insights, tacrolimus market top players
What is the current size and annual growth rate of the tacrolimus market?
The tacrolimus market size has grown strongly in recent years. It will grow from $6.59 billion in 2024 to $7.04 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to advancements in transplantation medicine, increased organ transplant procedures, regulatory approvals, expanded applications in dermatology, prevalence of autoimmune diseases, increased research investments, and enhanced drug delivery technologies.
The tacrolimus market size is expected to see strong growth in the next few years. It will grow to $9.01 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to expanded therapeutic applications, regulatory approvals for new indications, increased investment in research and development, growing awareness and acceptance of immunosuppressant therapies, expanding healthcare infrastructure in emerging markets, and evolving treatment guidelines and protocols. Major trends in the forecast period include increased adoption of personalized medicine approaches, advancements in drug delivery systems, expanding applications in autoimmune disorders, rising demand in emerging markets, growing emphasis on bioequivalence studies, development of novel formulations, and integration of pharmacogenomics for optimized dosing regimens.
Get Your Free Sample of The Global Tacrolimus Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15679&type=smp
Which major factors have contributed to the expansion of the tacrolimus market?
The increase in the number of procedures for organ transplants is expected to propel the growth of the tacrolimus market going forward. Organ transplantation is the surgical replacement of a malfunctioning organ by putting an organ or tissue from the donor into another (the recipient). Organ transplantation rates are in need due to progress in medical technology, enhancements in surgical methods, heightened awareness about organ donation, and enhanced post-transplantation care. Tacrolimus helps in organ transplantation by inhibiting T-cell activation and reducing cytokine production, thereby preventing the immune system from rejecting the transplanted organ. For instance, in January 2024, according to the US Department of Health and Human Services, a US-based government administration for health services, transplantation of organs from deceased and living donors totaled 46,632. This signifies a rise of 8.7% compared to 2022 and a 12.7% increase compared to 2021. Therefore, the increase in the number of procedures for organ transplants is driving the tacrolimus market.
How is the tacrolimus market segmented?
The tacrolimus market covered in this report is segmented –
1) By Product Type: Tacrolimus Capsules And Tablets, Tacrolimus Ointment, Tacrolimus Injection, Tacrolimus Granules
2) By Application: Immunosuppression, Dermatitis, Other Applications
3) By End User: Organ Transplant Centers, Hospitals, Clinics, Other End Users
Subsegments:
1) By Tacrolimus Capsules And Tablets: Oral Capsules, Oral Tablets
2) By Tacrolimus Ointment: Topical Ointment (0.03%), Topical Ointment (0.1%)
3) By Tacrolimus Injection: Injectable Solution, Injectable Powder
4) By Tacrolimus Granules: Oral Granules (For Suspension)
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/tacrolimus-global-market-report
Who are the top competitors in the tacrolimus market?
Major companies operating in the tacrolimus market are Sinopharm Chuankang Pharmaceutical, F. Hoffmann-La Roche AG, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sandoz Inc., Huadong Medicine Co Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., LEO Pharma A/S, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Wockhardt Limited, Biocon Ltd., Zydus Lifesciences Limited, Panacea Biotec, RPG Life Science, Sun Pharmaceutical Industries Limited, Tecoland Corporation
Which key trends are expected to influence the tacrolimus market in the coming years?
Major companies operating in the tacrolimus market are developing advanced medications, such as tacrolimus ointments to meet the growing demand for innovative treatments for dermatological conditions while also enhancing patient care. Tacrolimus ointment is a topical treatment containing tacrolimus, an immunosuppressive agent primarily used for treating inflammatory skin conditions. For instance, in August 2023, Glenmark, an India-based pharmaceutical company, obtained approval from the United States Food and Drug Administration (US FDA) for Tacrolimus Ointment 0.03%, which is the generic counterpart of Protopic Ointment 0.03%. Glenmark Pharmaceuticals will oversee the distribution of Tacrolimus Ointment, 0.03%, within the United States. This medication is prescribed to treat moderate-to-severe atopic dermatitis, a skin condition that causes inflammation, redness, and itching.
Which regional trends are influencing the tacrolimus market, and which area dominates theIndustry?
North America was the largest region in the tacrolimus market in 2024 and 2024. The regions covered in the tacrolimus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Tacrolimus Market Report 2025 Offer?
The tacrolimus market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Tacrolimus is an immunosuppressive medication used to prevent organ rejection post-transplantation. It functions by lowering immune system activity to stop the transplanted organ from being attacked by the immune system. Tacrolimus is used to prevent transplant rejection in the case of the kidney, heart, liver, or lung.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15679
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights fromIndustry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
